GSK vs SMCI
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 21, 2026
GSK
SMCI
Investment Advisor Scores
SMCI
AI Analyst Insights
Detailed Metrics Comparison
| Metric | GSK | SMCI | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 20.5339 | 9.7656 | SMCI |
| PEG Ratio | 102.7218 | 0.9132 | SMCI |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 5.3% | 93.2% | SMCI |
| Earnings Growth | -69.5% | 409.4% | SMCI |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 54.2/100 | 35.1/100 | GSK |
| Profit Margin | 14.5% | 5.7% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | STRONG BUY | EXTENDED | GSK |
Relative Price Performance (Last 90 Days)
Current Technical Phase
GSK
MarkupPrice above SMA50, rising 50-day trend (0.7% over 20 days), RSI 54
SMCI
NeutralMixed signals - no dominant trend phase, RSI 62
Fundamentals Snapshot
| Metric | GSK | SMCI |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 10.2 | 7.7 |
| Trailing P/E | 16.3 | 21.0 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.9% |
| Gross Margin | 0.7% | 0.1% |
| Operating Margin | 0.3% | 0.1% |
| EPS | 3.19 | 1.90 |
| Dividend Yield | 0.04% | — |